Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J R Hecht

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Human Pathology|February 24, 1999
Immunohistochemical evaluation of K-ras, p53, and HER-2/neu expression in hyperplastic, dysplastic, and carcinomatous lesions of the pancreas: evidence for multistep carcinogenesisS K Apple, J R Hecht, D N Lewin, et al.
American Journal of Clinical Pathology|March 1, 1996
Polymerase chain reaction-based K-ras mutation detection of pancreatic adenocarcinoma in routine cytology smearsS K Apple, J R Hecht, J M Novak, et al.
British Journal of Cancer|August 4, 2011
Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junctionZ A Wainberg, L-S Lin, B DiCarlo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2017
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Monotherapy Ontuxizumab (MORAb-004) Plus Best Supportive Care in Patients with Chemorefractory Metastatic Colorectal CancerAxel Grothey, Jonathan R Strosberg, Lindsay A Renfro, et al.
ESMO Open|March 2, 2023
Phase Ib study of talimogene laherparepvec in combination with atezolizumab in patients with triple negative breast cancer and colorectal cancer with liver metastasesJ R Hecht, S S Raman, A Chan, et al.
ESMO Gastrointestinal Oncology|April 23, 2026
Phase II randomised study of magrolimab combined with bevacizumab-FOLFIRI in patients with previously treated advanced inoperable metastatic colorectal cancerM Fakih, S Gill, K Sampat, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Human Pathology|February 24, 1999
Immunohistochemical evaluation of K-ras, p53, and HER-2/neu expression in hyperplastic, dysplastic, and carcinomatous lesions of the pancreas: evidence for multistep carcinogenesisS K Apple, J R Hecht, D N Lewin, et al.
American Journal of Clinical Pathology|March 1, 1996
Polymerase chain reaction-based K-ras mutation detection of pancreatic adenocarcinoma in routine cytology smearsS K Apple, J R Hecht, J M Novak, et al.
British Journal of Cancer|August 4, 2011
Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junctionZ A Wainberg, L-S Lin, B DiCarlo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2017
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Monotherapy Ontuxizumab (MORAb-004) Plus Best Supportive Care in Patients with Chemorefractory Metastatic Colorectal CancerAxel Grothey, Jonathan R Strosberg, Lindsay A Renfro, et al.
ESMO Open|March 2, 2023
Phase Ib study of talimogene laherparepvec in combination with atezolizumab in patients with triple negative breast cancer and colorectal cancer with liver metastasesJ R Hecht, S S Raman, A Chan, et al.
ESMO Gastrointestinal Oncology|April 23, 2026
Phase II randomised study of magrolimab combined with bevacizumab-FOLFIRI in patients with previously treated advanced inoperable metastatic colorectal cancerM Fakih, S Gill, K Sampat, et al.
Pageof 2